LYL 797
Alternative Names: LYL-797Latest Information Update: 12 Aug 2024
At a glance
- Originator Lyell Immunopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 08 Aug 2024 Lyell Immunopharma plans a phase I trial for Multiple myeloma and Chronic lymphocytic leukemia
- 07 Aug 2024 Lyell Immunopharma announces intention to submit IND for multiple myeloma and chronic lymphocytic leukemia in second half of 2024
- 26 Jun 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Triple negative breast cancer released by Lyell Immunopharma